Introduction {#s1}
============

Ovarian cancer is known as the most lethal genital system malignancy ([@B1]). It is also the fifth leading cause of cancer-related deaths in American women ([@B1]). In 2018, the estimated new ovarian cancer cases and deaths will be 22,240 and 14,070 in the US, respectively ([@B1]). In 2018, the age standardized incidence rate of ovarian cancer is 6.6 per 100,000 in world[^1^](#fn0001){ref-type="fn"}. Ovarian cancer can be divided into five histologic subtypes: serous tumor, mucinous tumor, endometrioid tumor, clear cell tumor, and other type of ovarian cancer. And the different histologic types of ovarian cancer may has different protective factors or pathogenic factors. Breastfeeding ([@B2]) and oral contraceptives ([@B3]) have been confirmed as protective factors in ovarian cancer. However, other exposures such as obesity ([@B4], [@B5]), diabetes ([@B6]), miscarriage ([@B7]) and a family history of breast/ovarian cancer ([@B8]) are demonstrated risk factors for ovarian cancer.

Menopausal hormone replacement therapy (HRT) is widely used to improve postmenopausal symptoms and ward off bone loss. However, in the past few years, many epidemiological studies have revealed that HRT is associated with an increased risk of breast cancer ([@B9], [@B10]). Data regarding HRT and the risk of ovarian cancer are contradictory. According to several studies, HRT is associated with an increased risk of ovarian cancer ([@B11]--[@B20]). However, several studies found no relationship between them ([@B21]--[@B37]) and others found the positive association in individual histological subtype ([@B38]--[@B46]). Although the increased risk of ovarian cancer associated with menopausal HRT has been described previously in several meta-analyses, the histological subtype of ovarian cancer was not taken into account ([@B47], [@B48]). Until now, whether the effect of HRT on the risk of ovarian cancer differs by histological subtype is not completely known. Therefore, we performed the current meta-analysis to evaluate the effect of menopausal HRT on ovarian cancer risk by histological subtype.

Materials and Methods {#s2}
=====================

Literature Search Strategy
--------------------------

We performed a literature search to identify relevant available articles from PubMed, Web of Science and EmBase from inception to August 2018 with no restrictions. Search terms included "hormone replacement therapy" (or "HRT") and "ovarian cancer" (or "ovarian neoplasms" or "ovarian carcinoma" or "ovary cancer"). The reference lists of the included studies were also reviewed for potential relevant studies.

Inclusion Criteria
------------------

Inclusion criteria were: (1) original report from observational studies; (2) menopausal HRT as the exposure of interest; (3) ovarian cancer as the outcome of interest; (4) relative risk ratio (RR) with 95% confidence interval (CI) provided. The most recent and complete study was selected if studies from the same population were repeated.

Two investigators searched and reviewed all relevant studies independently. Any disagreement was resolved by consensus with the involvement of a third reviewer.

Data Extraction
---------------

The following information were extracted from each study by two investigators independently: first author\'s name, published year, country, study design, follow-up duration, age range or mean age at baseline, sample size and number of cases, histological subtype of ovarian cancer, the types of hormones used in the study population, RR (we presented all results as RR for simplicity) with 95%CI and adjustment for potential confounders. We extracted RRs adjusted for the most confounding factors in the original studies. We prioritized the RRs for highest vs. lowest duration category of HRT use. If the study did not provide RRs for highest vs. lowest duration category of HRT use, we extracted the RRs for "use vs. non-use."

Statistical Analysis
--------------------

The Newcastle--Ottawa Scale was used to assess the quality of studies included in this meta-analysis. Pooled data were obtained as the inverse variance-weighted means of the logarithm of RRs with 95%CI to assess the associations of menopausal HRT and the risk of different histological subtypes of ovarian cancer, respectively. The DerSimonian and Laird random effects model (REM) was used to combine study-specific RRs (95%CIs). The *I*^2^ statistic was adopted to assess heterogeneity among studies (*I*^2^-values of 0, 25, 50, and 75% represented no, low, moderate and high heterogeneity, respectively). Meta-regression with restricted maximum likelihood estimation was performed to explore the important covariates that might have significant impact on between-study heterogeneity. Subgroup analyses were stratified on study design, geographic location and the types of hormones used in the study population. Sensitivity analysis was performed with one study removed at a time to assess whether the results could have been affected markedly by a single study. The funnel plot and Egger\'s test were performed to explore the small-study effect.

All statistical analyses were performed with STATA version 14.0 (Stata Corporation, College Station, TX, United States). All reported probabilities (*P*-values) were two-sided, with a statistical significance level of 0.05.

Results {#s3}
=======

Literature Search Results
-------------------------

We identified 2,445 articles by literature search, of which 2,387 were excluded after title and abstract review ([Figure 1](#F1){ref-type="fig"}). Three additional articles were found by searching the reference lists of included articles. Eleven articles with duplicate data from the same population, 13 reports without RR and/or 95%CI and one article assessing the risk of ovarian cancer mortality were excluded. Finally, 36 published articles were eligible for this meta-analysis.

![Flowchart of the study selection process based on PRISMA in this meta-analysis.](fendo-10-00801-g0001){#F1}

Characteristics of Studies
--------------------------

For the association of menopausal HRT with the risk of ovarian cancer, 34 articles ([@B11]--[@B28], [@B30]--[@B42], [@B44]--[@B46]) (15 cohort and 19 case-control studies) were included, involving 3,305,108 participants. The Newcastle-Ottawa Scale indicated that most of the studies included in this meta-analysis were of high quality (thirty of them scored more than seven). Among these studies, 15 were performed in Europe, 15 in North America, 2 in Asia and 2 in Australia. For the association of menopausal HRT and the risk of ovarian cancer by histological subtype, 12 studies ([@B21], [@B29], [@B35], [@B38]--[@B46]) assessing 1,193,201 participants were included for serous tumors, 10 reports ([@B21], [@B38]--[@B46]) evaluating 1,173,009 participants were included for endometrioid tumors, 9 studies ([@B35], [@B38]--[@B45]) assessing 1,089,421 participants were included for mucinous tumors, 5 reports ([@B21], [@B39], [@B41], [@B43], [@B45]) with 1,081,067 participants were included for clear cell tumors and 5 studies ([@B38], [@B39], [@B41], [@B44], [@B45]) evaluating 175,429 participants were included for other types of ovarian cancer. The detailed characteristics of the included studies are shown in [Table 1](#T1){ref-type="table"}.

###### 

The detailed characteristics of the included studies.

  **References**                     **Country (year)**             **Age**                                   **Study design**   **Years of follow-up**                **Participants (cases)**   **Cancer type**                 **Hormone type**   **RR (95% CI)**      **Adjustment for covariant**
  ---------------------------------- ------------------------------ ----------------------------------------- ------------------ ------------------------------------- -------------------------- ------------------------------- ------------------ -------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Danforth et al. ([@B46])           America (2007)                 61.2 (mean)                               Cohort             26 years                              82,950 (389)               Ovarian cancer                  HRT                1.41 (1.07, 1.86)    Age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause, age at menarche
  Danforth et al. ([@B46])           America (2007)                 61.2 (mean)                               Cohort             26 years                              82,950 (233)               Serous tumors                   HRT                1.66 (1.17, 2.36)    Age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause, age at menarche
  Danforth et al. ([@B46])           America (2007)                 61.2 (mean)                               Cohort             26 years                              82,950 (60)                Endometrioid tumors             HRT                1.86 (0.89, 3.91)    Age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause, age at menarche
  Bethea et al. ([@B30])             America (2017)                 37.8 ± 10.3                               Cohort             18 years                              59,000 (115)               Ovarian cancer                  HRT                1.42 (0.75, 2.70)    Age, questionnaire cycle, parity, lactation, age at first birth, age at last birth, hysterectomy, tubal ligation, oral contraceptive use, educational HRT attainment, and BMI
  Li et al. ([@B25])                 10 European countries (2015)   52.4 (median)                             Cohort             11.7 years                            367,903 (791)              Ovarian cancer                  HRT                1.09 (0.92, 1.30)    Menopausal status, age at menopause, age at menarche, number of full-term pregnancies (FTPs), age at first FTP, duration of breast-feeding, number of miscarriages, unilateral ovariectomy, hysterectomy, HRT, OC use, IUD use, BMI, smoking status, alcohol consumption, and pre-existing diabetes
  Soegaard et al. ([@B38])           Denmark (2007)                 35-79                                     Case control       NA                                    1,614 (50)                 Mucinous tumors                 HRT                0.71 (0.37, 1.36)    Age, pregnancy, additional pregnancies and duration of oral contraceptive use
  Soegaard et al. ([@B38])           Denmark (2007)                 35-79                                     Case control       NA                                    1,907 (343)                Serous tumors                   HRT                1.30 (1.00, 1.68)    Age, pregnancy, additional pregnancies and duration of oral contraceptive use
  Soegaard et al. ([@B38])           Denmark (2007)                 35-79                                     Case control       NA                                    1,639 (75)                 Endometrioid tumors             HRT                1.75 (1.07, 2.84)    Age, pregnancy, additional pregnancies and duration of oral contraceptive use
  Soegaard et al. ([@B38])           Denmark (2007)                 35-79                                     Case control       NA                                    1,650 (86)                 Other types of ovarian cancer   HRT                1.43 (0.90, 2.28)    Age, pregnancy, additional pregnancies and duration of oral contraceptive use
  Soegaard et al. ([@B38])           Denmark (2007)                 35-79                                     Case control       NA                                    2,118 (554)                Ovarian cancer                  HRT                1.30 (1.05, 1.61)    Age, pregnancy, additional pregnancies and duration of oral contraceptive use
  Koskela-Niska et al. ([@B39])      Finland (2013)                 \> 50                                     Case control       NA                                    15,283 (3,958)             Ovarian cancer                  HRT                1.15 (0.99, 1.32)    Age and place of residence
  Koskela-Niska et al. ([@B39])      Finland (2013)                 \> 50                                     Case control       NA                                    7,333 (1,903)              Serous tumors                   HRT                1.45 (1.20, 1.75)    Age and place of residence
  Koskela-Niska et al. ([@B39])      Finland (2013)                 \> 50                                     Case control       NA                                    2,901 (748)                Endometrioid tumors             HRT                1.25 (0.88, 1.76)    Age and place of residence
  Koskela-Niska et al. ([@B39])      Finland (2013)                 \> 50                                     Case control       NA                                    1,611 (417)                Mucinous tumors                 HRT                0.35 (0.19, 0.67)    Age and place of residence
  Koskela-Niska et al. ([@B39])      Finland (2013)                 \> 50                                     Case control       NA                                    596 (155)                  Clear cell tumors               HRT                0.72 (0.23, 2.29)    Age and place of residence
  Koskela-Niska et al. ([@B39])      Finland (2013)                 \> 50                                     Case control       NA                                    2,842 (735)                Other types of ovarian cancer   HRT                0.82 (0.56, 1.20)    Age and place of residence
  Folsom et al. ([@B11])             America (2004)                 55-69                                     Cohort             15 years                              31,381 (174)               Ovarian cancer                  ERT                2.53 (1.44, 4.45)    Age, family history of ovarian cancer in a first- or second-degree relative, hysterectomy, unilateral oophorectomy, number of live births, physical activity index, pack-years of smoking, waist/hip ratio, and BMI
  Risch ([@B40])                     Canada (1996)                  Case: 59.5, control: 57.5 (mean)          Case control       NA                                    776 (212)                  Serous tumors                   ERT                2.03 (1.04, 3.97)    Age, number of full-term pregnancies, total years of oral-contraceptive use, and average lactation/pregnancy as continuous terms, and history of tubal ligation, hysterectomy, and mother/sister with breast cancer as dichotomous terms
  Risch ([@B40])                     Canada (1996)                  Case: 59.5, control: 57.5 (mean)          Case control       NA                                    637 (73)                   Endometrioid tumors             ERT                2.81 (1.15, 6.89)    Age, number of full-term pregnancies, total years of oral-contraceptive use, and average lactation/pregnancy as continuous terms, and history of tubal ligation, hysterectomy, and mother/sister with breast cancer as dichotomous terms
  Risch ([@B40])                     Canada (1996)                  Case: 59.5, control: 57.5 (mean)          Case control       NA                                    604 (40)                   Mucinous tumors                 ERT                0.58 (0.08, 4.21)    Age, number of full-term pregnancies, total years of oral-contraceptive use, and average lactation/pregnancy as continuous terms, and history of tubal ligation, hysterectomy, and mother/sister with breast cancer as dichotomous terms
  Risch ([@B40])                     Canada (1996)                  Case: 59.5, control: 57.5 (mean)          Case control       NA                                    891 (327)                  Ovarian cancer                  ERT                1.77 (0.98, 3.20)    Age, number of full-term pregnancies, total years of oral-contraceptive use, and average lactation/pregnancy as continuous terms, and history of tubal ligation, hysterectomy, and mother/sister with breast cancer as dichotomous terms
  Perri et al. ([@B12])              Israeli (2015)                 Case: 53.6 ± 10.3, control: 49.1 ± 13.4   Cohort             18 years                              1,073 (175)                Ovarian cancer                  HRT                1.98 (1.21, 3.25)    Mutation type, age at menarche, oral contraceptive use, parity, age at first pregnancy
  Bakken et al. ([@B26])             Norway (2004)                  53.0 (mean)                               Cohort             7 years                               30,115 (74)                Ovarian cancer                  HRT                1.30 (0.80, 2.00)    Age, BMI, smoking, ever use of OCs, time since menopause, parity and age at last birth
  Mills et al. ([@B41])              America (2005)                 NA                                        Case control       NA                                    1,378 (256)                Ovarian cancer                  HRT                1.39 (1.01, 1.93)    Age, race/ethnicity, duration of oral contraceptive use and breastfeeding
  Mills et al. ([@B41])              America (2005)                 NA                                        Case control       NA                                    1,214 (92)                 Serous tumors                   HRT                1.61 (0.99, 2.60)    Age, race/ethnicity, duration of oral contraceptive use and breastfeeding
  Mills et al. ([@B41])              America (2005)                 NA                                        Case control       NA                                    1,157 (35)                 Endometrioid tumors             HRT                0.96 (0.44, 2.10)    Age, race/ethnicity, duration of oral contraceptive use and breastfeeding
  Mills et al. ([@B41])              America (2005)                 NA                                        Case control       NA                                    1,138 (16)                 Mucinous tumors                 HRT                1.32 (0.40, 4.40)    Age, race/ethnicity, duration of oral contraceptive use and breastfeeding
  Mills et al. ([@B41])              America (2005)                 NA                                        Case control       NA                                    1,134 (12)                 Clear cell tumors               HRT                1.14 (0.27, 4.84)    Age, race/ethnicity, duration of oral contraceptive use and breastfeeding
  Mills et al. ([@B41])              America (2005)                 NA                                        Case control       NA                                    1,149 (27)                 Other types of ovarian cancer   HRT                1.30 (0.57, 2.97)    Age, race/ethnicity, duration of oral contraceptive use and breastfeeding
  Purdie et al. ([@B23])             Australia (1999)               18-79                                     Case control       NA                                    1,648 (793)                Ovarian cancer                  HRT                1.20 (0.90, 1.60)    Age, education, area of residence, BMI, hysterectomy, tubal sterilization, talc use in perineal region, smoking status, duration of OCP use, parity and a family history of breast or ovarian cancer
  Riman et al. ([@B42])              Sweden (2002)                  Case: 62.4 ± 7.4, control: 63.4 ± 7.1     Case control       NA                                    4,432 (642)                Ovarian cancer                  ERT                2.10 (0.99, 4.48)    Age, parity,BMI (kg/m^2^), age at menopause, hysterectomy,duration of oral contraceptive use, and ever use of estrogen only (estrogen replacement therapy \[ERT\]) and continuous estrogen--progestin combinations (HRTcp) as categorized variables
  Riman et al. ([@B42])              Sweden (2002)                  Case: 62.6 ± 7.3, control: 63.4 ± 7.1     Case control       NA                                    4,123 (333)                Serous tumors                   ERT                2.51 (1.00, 6.34)    Age, parity,BMI (kg/m^2^), age at menopause, hysterectomy,duration of oral contraceptive use, and ever use of estrogen only (estrogen replacement therapy \[ERT\]) and continuous estrogen--progestin combinations (HRTcp) as categorized variables
  Riman et al. ([@B42])              Sweden (2002)                  Case: 61.6 ± 7.6, control: 63.4 ± 7.1     Case control       NA                                    3,967 (177)                Endometrioid tumors             ERT                2.24 (0.64, 7.89)    Age, parity,BMI (kg/m^2^), age at menopause, hysterectomy,duration of oral contraceptive use, and ever use of estrogen only (estrogen replacement therapy \[ERT\]) and continuous estrogen--progestin combinations (HRTcp) as categorized variables
  Riman et al. ([@B42])              Sweden (2002)                  Case: 62.5 ± 7.8, control: 63.4 ± 7.1     Case control       NA                                    3,850 (60)                 Mucinous tumors                 ERT                1.59 (0.19, 13.33)   Age, parity,BMI (kg/m^2^), age at menopause, hysterectomy,duration of oral contraceptive use, and ever use of estrogen only (estrogen replacement therapy \[ERT\]) and continuous estrogen--progestin combinations (HRTcp) as categorized variables
  Kotsopoulos et al. ([@B22])        America (2006)                 Case: 62.7, control: 61.2 (mean)          Case control       NA                                    537 (162)                  Ovarian cancer                  HRT                0.93 (0.56, 1.56)    Parity, OC use and country of residence
  Hempling et al. ([@B21])           America (1997)                 Case: 54.9, control: 54.9 (mean)          Case control       NA                                    1,255 (499)                Ovarian cancer                  HRT                0.60 (0.30, 1.40)    Age at diagnosis, parity, oral contraceptive use, smoking history, family history of epithelial ovarian cancer, age at menarche, menopausal status, income, location, and education
  Hempling et al. ([@B21])           America (1997)                 Case: 54.9, control: 54.9 (mean)          Case control       NA                                    NA                         Serous tumors                   HRT                1.20 (0.80, 1.70)    NA
  Hempling et al. ([@B21])           America (1997)                 Case: 54.9, control: 54.9 (mean)          Case control       NA                                    NA                         Clear cell tumors               HRT                1.10 (0.40, 3.40)    NA
  Hempling et al. ([@B21])           America (1997)                 Case: 54.9, control: 54.9 (mean)          Case control       NA                                    NA                         Endometrioid tumors             HRT                0.40 (0.20, 1.20)    NA
  Sit et al. ([@B24])                America (2002)                 Case: 56.6, control: 55.7 (mean)          Case control       NA                                    1,410 (848)                Ovarian cancer                  HRT                1.03 (0.69, 1.53)    Numbers of live births, family history of ovarian carcinoma,OC use, history of tubal ligation, and age at diagnosis
  Mørch et al. ([@B43])              Denmark (2012)                 ≥50                                       Cohort             8 years                               909,946 (1,336)            Serous tumors                   HRT                1.64 (1.41, 1.89)    Age, time period, number of births, educational level, and history of hysterectomy, sterilization, unilateral oophorectomy or salpingo-oophorectomy, endometriosis, and infertility
  Mørch et al. ([@B43])              Denmark (2012)                 ≥50                                       Cohort             8 years                               909,946 (377)              Endometrioid tumors             HRT                1.81 (1.39, 2.36)    Age, time period, number of births, educational level, and history of hysterectomy, sterilization, unilateral oophorectomy or salpingo-oophorectomy, endometriosis, and infertility
  Mørch et al. ([@B43])              Denmark (2012)                 ≥50                                       Cohort             8 years                               909,946 (293)              Mucinous tumors                 HRT                0.74 (0.51, 1.08)    Age, time period, number of births, educational level, and history of hysterectomy, sterilization, unilateral oophorectomy or salpingo-oophorectomy, endometriosis, and infertility
  Mørch et al. ([@B43])              Denmark (2012)                 ≥50                                       Cohort             8 years                               909,946 (159)              Clear cell tumors               HRT                0.81 (0.50, 1.32)    Age, time period, number of births, educational level, and history of hysterectomy, sterilization, unilateral oophorectomy or salpingo-oophorectomy, endometriosis, and infertility
  Morch et al. ([@B13])              Denmark (2009)                 ≥50                                       Cohort             8 years                               909,946 (2,297)            Ovarian cancer                  HRT                1.57 (1.26, 1.95)    Age, period of use, number of births, hysterectomy, sterilization, unilateral oophorectomy or salpingo-oophorectomy, endometriosis, infertility, and educational status
  Wernli et al. ([@B27])             America (2008)                 40-79                                     Case control       NA                                    6,559 (751)                Ovarian cancer                  HRT                1.24 (0.97, 1.60)    BMI, oral contraceptive use, tubal ligation, parity, family history of ovarian cancer, hysterectomy, and menopausal status
  Urban et al. ([@B14])              America (2015)                 50-79                                     Cohort             12.3 years                            74,786 (461)               Ovarian cancer                  HRT                1.50 (1.23, 1.83)    Age and race
  Tavani et al. ([@B15])             Italy (2000)                   Case: 54.0, control: 52.0 (mean)          Case control       NA                                    232 (93)                   Ovarian cancer                  HRT                1.80 (1.30, 2.60)    Age and area of residence
  Lacey et al. ([@B16])              America (2002)                 56.6 (mean)                               Cohort             13.4 years                            44,241 (275)               Ovarian cancer                  ERT                3.20 (1.70, 5.70)    Age, menopause type, and duration of oral contraceptive use
  Simin et al. ([@B17])              Sweden (2017)                  ≥40                                       Cohort             7 years                               290,186 (573)              Ovarian cancer                  HRT                1.09 (1.00, 1.19)    NA
  Yang et al. ([@B45])               America (2012)                 Case: 62.8 ± 5.3, control: 61.8 ± 5.4     Cohort             Case: 5.1 years; control: 9.8 years   168,323 (849)              Ovarian cancer                  HRT                1.57 (1.31, 1.89)    Age, oral contraceptive use, parity, menopausal hormone therapy
  Yang et al. ([@B45])               America (2012)                 Case: 62.6 ± 5.4, control: 61.8 ± 5.4     Cohort             Case: 5.1 years; control: 9.8 years   168,323 (449)              Serous tumors                   HRT                1.64 (1.27, 2.13)    Age, oral contraceptive use, parity, menopausal hormone therapy
  Yang et al. ([@B45])               America (2012)                 Case: 61.0 ± 6.2, control: 61.8 ± 5.4     Cohort             Case: 5.1 years; control: 9.8 years   168,323 (78)               Endometrioid tumors             HRT                2.27 (1.26, 4.09)    Age, oral contraceptive use, parity, menopausal hormone therapy
  Yang et al. ([@B45])               America (2012)                 Case: 63.5 ± 5.5, control: 61.8 ± 5.4     Cohort             Case: 5.1 years; control: 9.8 years   169,391 ([@B37])           Mucinous tumors                 HRT                0.50 (0.17, 1.42)    Age, oral contraceptive use, parity, menopausal hormone therapy
  Yang et al. ([@B45])               America (2012)                 Case: 59.7 ± 6.2, control: 61.8 ± 5.4     Cohort             Case: 5.1 years; control: 9.8 years   168,323 ([@B26])           Clear cell tumors               HRT                1.82 (0.64, 5.17)    Age, oral contraceptive use, parity, menopausal hormone therapy
  Yang et al. ([@B45])               America (2012)                 Case: 63.9 ± 4.8, control: 61.8 ± 5.4     Cohort             Case: 5.1 years; control: 9.8 years   168,323 (255)              Other types of ovarian cancer   HRT                1.53 (1.11, 2.13)    Age, oral contraceptive use, parity, menopausal hormone therapy
  Rossing et al. ([@B18])            America (2007)                 Case: 47.0, control: 48.0 (median)        Case control       NA                                    1,818 (715)                Ovarian cancer                  ERT                1.60 (1.10, 2.50)    Age, county of residence, year of diagnosis/reference date, number of full-term pregnancies, and duration of hormonal contraception
  Moorman et al. ([@B44])            America (2005)                 20-74                                     Case control       NA                                    734 (364)                  Ovarian cancer                  HRT                1.20 (0.80, 1.60)    Age, race, parity, tubal ligation, hysterectomy, BMI 1 year before interview, 1st degree family history of breast or ovarian cancer, breastfeeding, oral contraceptive use, and educational level
  Moorman et al. ([@B44])            America (2005)                 20-74                                     Case control       NA                                    572 (216)                  Serous tumors                   HRT                2.00 (1.30, 3.10)    Age and race
  Moorman et al. ([@B44])            America (2005)                 20-74                                     Case control       NA                                    421 (65)                   Endometrioid tumors             HRT                1.00 (0.50, 2.00)    Age and race
  Moorman et al. ([@B44])            America (2005)                 20-74                                     Case control       NA                                    382 ([@B25])               Mucinous tumors                 HRT                0.90 (0.30, 2.50)    Age and race
  Moorman et al. ([@B44])            America (2005)                 20-74                                     Case control       NA                                    397 ([@B40])               Other types of ovarian cancer   HRT                1.10 (0.50, 2.70)    Age and race
  Beral et al. ([@B19])              United Kingdom (2007)          57.2 ± 4.6                                Cohort             5.3 years                             948,576 (2,273)            Ovarian cancer                  HRT                1.31 (1.12, 1.53)    Region of residence, socioeconomic group,time since menopause, parity, BMI, alcohol consumption, and use of oral contraceptives
  Koskela-Niska et al. ([@B39])      Finland (2013)                 ≥50                                       Cohort             12 years                              224,015 (602)              Ovarian cancer                  HRT                1.13 (0.74, 1.64)    Age
  Rasmussen et al. ([@B29])          Denmark (2017)                 NA                                        Case control       NA                                    14,007 (885)               Ovarian cancer                  HRT                1.34 (0.86, 2.09)    Age, tubal ligation, salpingectomy, hysterectomy, endometriosis, pelvic inflammatory disease, infertility, parity, and hormone replacement therapy
  Chiaffarino et al. ([@B31])        Italy (2001)                   Case: 56.0, control: 57.0 (median)        Case control       NA                                    3,442 (1031)               Ovarian cancer                  HRT                1.40 (0.80, 2.50)    Age, center education, parity, OC use. and family history of ovarian and breast cancer in first degree relative
  Braem et al. ([@B32])              Netherlands (2010)             Case: 62.0, control: 61.5 (mean)          cohort             16 years                              2,706 (375)                Ovarian cancer                  HRT                0.97 (0.69, 1.37)    Age, parity, duration of OC and HRT use
  Pasalich et al. ([@B33])           China (2013)                   Case: 59.0 ± 5.6, control: 59.7 ± 6.4     Case control       NA                                    1,000 (500)                Ovarian cancer                  HRT                1.05 (0.35, 3.21)    Age, smoking status, alcohol drinking, education, BMI,mutually adjusted for parity, oral contraceptive use, hormone replacement therapy, menopausal status, hysterectomy and family history of ovarian and/or breast cancer
  Salazar-Martinez et al. ([@B34])   Mexico (1999)                  Case: 52.8, control: 54.6 (mean)          Case control       NA                                    752 (84)                   Ovarian cancer                  HRT                1.00 (0.36, 2.70)    Age, anovulatory index, smoking, diabetes mellitus, hypertension, physical activity, menopausal status, and body build index
  Jordan et al. ([@B35])             Australia (2007)               18-79                                     Case control       NA                                    885 (133)                  Mucinous tumors                 HRT                0.67 (0.28, 1.64)    Age, state of residence, education, parity, hysterectomy, smoking status
  Jordan et al. ([@B35])             Australia (2007)               18-79                                     Case control       NA                                    982 (230)                  Serous tumors                   HRT                0.71 (0.40, 1.27)    Age, state of residence, education, parity, hysterectomy, smoking status
  Jordan et al. ([@B35])             Australia (2007)               18-79                                     Case control       NA                                    1,115 (363)                Ovarian cancer                  HRT                0.70 (0.42, 1.17)    Age, state of residence, education, parity, hysterectomy, smoking status
  Polychronopoulou et al. ([@B20])   Greece (1993)                  \<75                                      Case control       NA                                    389 (189)                  Ovarian cancer                  HRT                5.73 (1.07, 30.80)   Age, years of schooling, weight before the disease, age at menarche, parity and age at first birth
  Adami et al. ([@B36])              Sweden (1989)                  54.5 (mean)                               cohort             6.7 years                             23,244 (64)                Ovarian cancer                  HRT                0.96 (0.74, 1.23)    NA
  Schneider et al. ([@B37])          United Kingdom (2009)          51.3 ± 6.1                                Case control       NA                                    602 (86)                   Ovarian cancer                  HRT                0.97 (0.61, 1.54)    Smoking status, BMI, use of oral contraceptives, progesterone preparations and vaginal estrogens

*RR, relative risk; CI, confidence interval; BMI, body mass index; NA, not available; HRT, hormone replacement therapy; ERT, estrogen replacement therapy*.

Quantitative Synthesis
----------------------

The association of menopausal HRT with the risk of ovarian cancer is summarized in [Table 2](#T2){ref-type="table"}.

###### 

Summary risk estimates of the association between hormone replacement therapy and ovarian cancer.

  **Subgroup**                              **No. of studies**   **Pooled RR (95% CI)**   ***I*^**2**^ (%)**   ***P*~**heterogeneity**~**
  ----------------------------------------- -------------------- ------------------------ -------------------- ----------------------------
  All studies                               34                   1.29 (1.19--1.40)        57.4                 \<0.001
  After excluding two studies (RR \> 3.0)   32                   1.27 (1.17--1.37)        52.1                 \<0.001
  **Study design**                                                                                             
  Cohort studies                            15                   1.35 (1.19--1.53)        72.9                 \<0.001
  Case control studies                      19                   1.24 (1.11--1.38)        30.4                 0.103
  **Hormones types**                                                                                           
  HRT                                       28                   1.24 (1.15--1.35)        51.6                 0.001
  ERT                                       6                    1.85 (1.28--2.66)        75.1                 0.001
  **Geographic location**                                                                                      
  North America                             15                   1.41 (1.23--1.61)        45.5                 0.028
  Europe                                    15                   1.22 (1.12--1.34)        52.6                 0.009
  Asia                                      2                    1.76 (1.09--2.85)        4.8                  0.305
  Australia                                 2                    0.96 (0.57--1.61)        69.1                 0.072

*RR, relative risk; CI, confidence interval; HRT, hormone replacement therapy; ERT, estrogen replacement therapy*.

The pooled RR of menopausal HRT and the risk of ovarian cancer was 1.29 (95%CI 1.19--1.40, *I*^2^ = 57.4%, *P*~heterogeneity~ \< 0.001, [Figure 2](#F2){ref-type="fig"}). In subgroup analysis stratified by study design, pooled RRs in cohort and case-control studies were 1.35 (95%CI 1.19--1.53, *I*^2^ = 72.9%, *P*~heterogeneity~ \< 0.001) and 1.24 (95%CI 1.11--1.38, *I*^2^ = 30.4%, *P*~heterogeneity~ = 0.103), respectively ([Figure 3](#F3){ref-type="fig"}). In subgroup analysis stratified by geographic location, significant positive associations were found for North America (RR = 1.41, 95%CI 1.23--1.61, *I*^2^ = 45.5%, *P*~heterogeneity~ = 0.028), Europe (RR = 1.22, 95%CI 1.12--1.34, *I*^2^ = 52.6%, *P*~heterogeneity~ = 0.009), and Asia (RR = 1.76, 95%CI 1.09--2.85, *I*^2^ = 4.8%, *P*~heterogeneity~ = 0.305), but not Australia (RR = 0.96, 95%CI 0.57--1.61, *I*^2^ = 69.1%, *P*~heterogeneity~ = 0.072) ([Figure S1](#SM1){ref-type="supplementary-material"}). In subgroup analysis stratified by the hormones types, pooled RRs for HRT and ERT (estrogen replacement therapy) were 1.24 (95%CI 1.15--1.35, *I*^2^ = 51.6%, *P*~heterogeneity~ = 0.001) and 1.85 (95%CI 1.28--2.66, *I*^2^ = 75.1%, *P*~heterogeneity~ = 0.001), respectively ([Figure S2](#SM2){ref-type="supplementary-material"}).

![Forest plot of menopausal HRT and the risk of ovarian cancer. The size of a gray box is proportional to the weight assigned to the respective study, and horizontal lines represent 95% confidence intervals (CIs).](fendo-10-00801-g0002){#F2}

![Forest plot of menopausal HRT and the risk of ovarian cancer in subgroup analysis stratified by study design. The size of a gray box is proportional to the weight assigned to the respective study, and horizontal lines represent 95% confidence intervals (CIs).](fendo-10-00801-g0003){#F3}

The associations of menopausal HRT with the risk of ovarian cancer in various histological subtypes are summarized in [Table 3](#T3){ref-type="table"}.

###### 

Summary risk estimates of the association between hormone replacement therapy and ovarian cancer by histologic subtype.

  **Histologic subtype of ovarian cancer**   **Subgroup**             **No. of studies**   **Pooled RR(95% CI)**   ***I*^**2**^ (%)**   ***P*~***heterogeneity***~**
  ------------------------------------------ ------------------------ -------------------- ----------------------- -------------------- ------------------------------
  Serous tumor                               All studies              12                   1.50 (1.35--1.68)       27.5                 0.175
                                             Study design                                                                               
                                               Cohort studies         3                    1.64 (1.46--1.85)       0.0                  0.998
                                               Case control studies   9                    1.42 (1.20--1.67)       33.6                 0.149
                                             Continent                                                                                  
                                               North America          6                    1.61 (1.38--1.88)       0.0                  0.578
                                               Europe                 5                    1.51 (1.36--1.68)       2.7                  0.391
                                               Australia              1                    0.71 (0.40--1.27)       NA                   NA
                                             Hormones types                                                                             
                                               HRT                    9                    1.48 (1.29--1.70)       38.8                 0.109
                                               ERT                    3                    1.54 (1.25--1.89)       4.3                  0.352
  Mucinous                                   All studies              9                    0.66 (0.52--0.85)       0.0                  0.553
  tumor                                      Study design                                                                               
                                               Cohort studies         2                    0.71 (0.50--1.01)       0.0                  0.495
                                               Case control studies   7                    0.62 (0.44--0.89)       1.9                  0.410
                                             Continent                                                                                  
                                               North America          4                    0.79 (0.43--1.44)       0.0                  0.666
                                               Europe                 4                    0.62 (0.40--0.94)       38.8                 0.179
                                               Australia              1                    0.67 (0.28--1.62)       NA                   NA
                                             Hormones types                                                                             
                                               HRT                    6                    0.74 (0.58--0.97)       0.0                  0.900
                                               ERT                    3                    0.41 (0.23--0.73)       0.0                  0.383
  Endometrioid                               All studies              10                   1.48 (1.13--1.94)       51.8                 0.028
  tumor                                      Study design                                                                               
                                               Cohort studies         3                    1.88 (1.49--2.36)       0.0                  0.789
                                               Case control studies   7                    1.25 (0.86--1.82)       53.1                 0.046
                                             Continent                                                                                  
                                               North America          6                    1.32 (0.78--2.23)       66.2                 0.011
                                               Europe                 4                    1.61 (1.32--1.97)       5.5                  0.365
                                             Hormones types                                                                             
                                               HRT                    7                    1.40 (0.99--1.98)       60.2                 0.020
                                               ERT                    3                    1.68 (0.97--2.91)       38.6                 0.196
  Clear cell                                 All studies              5                    0.94 (0.65--1.36)       0.0                  0.689
  tumor                                      Study design                                                                               
                                               Cohort studies         2                    1.06 (0.50--2.23)       47.3                 0.168
                                               Case control studies   3                    0.95 (0.48--1.90)       0.0                  0.837
                                             Continent                                                                                  
                                               North America          3                    1.36 (0.70--2.64)       0.0                  0.776
                                               Europe                 2                    0.80 (0.51--1.24)       0.0                  0.853
                                             Hormones types                                                                             
                                               HRT                    4                    0.97 (0.66--1.44)       0.0                  0.567
                                               ERT                    1                    0.72 (0.23--2.27)       NA                   NA
  Other type of                              All studies              5                    1.21 (0.91--1.61)       39.0                 0.161
  ovarian cancer                             Study design                                                                               
                                               Cohort studies         1                    1.53 (1.10--2.12)       NA                   NA
                                               Case control studies   4                    1.08 (0.80--1.45)       16.2                 0.311
                                             Continent                                                                                  
                                               North America          3                    1.44 (1.09--1.92)       0.0                  0.747
                                               Europe                 2                    1.07 (0.62--1.84)       69.6                 0.070
                                             Hormones types                                                                             
                                               HRT                    4                    1.44 (1.13--1.84)       0.0                  0.900
                                               ERT                    1                    0.82 (0.56--1.20)       NA                   NA

*RR, relative risk; CI, confidence interval*.

In the five major histologic subtypes, significant positive associations were observed in serous (RR = 1.50, 95%CI 1.35--1.68, *I*^2^ = 27.5%, *P*~heterogeneity~ = 0.175) and endometrioid (RR = 1.48, 95%CI 1.13--1.94, *I*^2^ = 51.8%, *P*~heterogeneity~ = 0.028) tumors. In subgroup analysis stratified by study design, pooled RRs for serous tumors in cohort and case-control studies were 1.64 (95%CI 1.46--1.85, *I*^2^ = 0.0%, *P*~heterogeneity~ = 0.998) and 1.42 (95%CI 1.20--1.67, *I*^2^ = 33.6%, *P*~heterogeneity~ = 0.149), respectively. In subgroup analysis stratified by continent, significant positive associations were found for North America (RR = 1.61, 95%CI 1.38--1.88, *I*^2^ = 0.0%, *P*~heterogeneity~ = 0.578) and Europe (RR = 1.51, 95%CI 1.36--1.68, *I*^2^ = 2.7%, *P*~heterogeneity~ = 0.391), respectively. In subgroup analysis stratified by the hormones types, pooled RRs for HRT and ERT were 1.48 (95%CI 1.29--1.70, *I*^2^ = 38.8%, *P*~heterogeneity~ = 0.109) and 1.54 (95%CI 1.25--1.89, *I*^2^ = 4.3%, *P*~heterogeneity~ = 0.352), respectively. In subgroup analysis for endometrioid tumors, significant positive associations were obtained in cohort studies (RR = 1.88, 95%CI 1.49--2.36, *I*^2^ = 0.0%, *P*~heterogeneity~ = 0.789) and Europe (RR = 1.61, 95%CI 1.32--1.97, *I*^2^ = 5.5%, *P*~heterogeneity~ = 0.365), respectively.

Meta-Regression and Sensitivity Analysis
----------------------------------------

To assess between-study heterogeneity, we performed univariate meta-regression with the covariates of study design, publication year and continent. However, none of these covariates was found to have a significant impact on between-study heterogeneity. After excluding two study ([@B16], [@B20]) (RR \> 3.0) in the ovarian cancer assessment, the heterogeneity remained at a moderate level (*I*^2^ = 52.1%, *P*~heterogeneity~ \< 0.001), and the pooled RR was 1.27 (95%CI 1.17--1.37).

In sensitivity analysis excluding one study at a time, pooled RRs (95%CIs) of the association of menopausal HRT with the risk of ovarian cancer ranged from 1.27 (95%CI 1.18--1.38) to 1.31 (95%CI 1.20--1.42). No individual study had excessive effect on the pooled RR.

Publication Bias
----------------

Visual inspection of the funnel plot ([Figure S3](#SM3){ref-type="supplementary-material"}) and Egger\'s test (*P*~ovarian\ cancer~ = 0.083) showed no evidence of significant small-study effect for the association of menopausal HRT with the risk of ovarian cancer. Egger\'s test also provided no evidence of significant small-study effect for the association of menopausal HRT with the risk of ovarian cancer by histologic subtype (*P*~serous\ tumor~ = 0.762, *P*~endometrioid\ tumor~ = 0.550, *P*~mucinous\ tumor~ = 0.655, *P*~clear\ call\ tumor~ = 0.349, *P*~other\ types\ of\ ovarian\ cancer~ = 0.892).

Discussion {#s4}
==========

The current meta-analysis assessed associations of menopausal HRT with the risk of ovarian cancer in various histologic subtypes. Findings of this meta-analysis indicated a positive association of menopausal HRT with the risk of ovarian cancer. In subgroup analysis by study design, significant positive associations were observed in both cohort and case control studies. In subgroup analysis by histologic subtypes, we found that menopausal HRT may increase the risk of serous and endometrioid tumors. In subgroup analysis by the hormones types, significant positive associations were observed for both HRT and ERT. The pooled RR indicated that there might be a stronger association in ERT users, but the result might be not true enough with the insufficient studies about ERT.

The mechanism underlying the association of menopausal HRT with ovarian cancer is not well-understood. A theory suggests that high levels of gonadotropins during menopause act as a promoter on the affected ovarian tissue ([@B49]). These findings imply that menopausal HRT might decrease the risk of cancer by reducing the levels of gonadotropins. However, these benefits might be outweighed by estrogen-induced ovarian cell proliferation ([@B50]). Estrogen and progesterone receptors are found in normal ovarian surface and most of ovarian tumors are estrogen receptor-positive ([@B51], [@B52]). Estrogen could stimulate the proliferation of ovarian surface epithelial cells and progesterone could promote the apoptosis of ovarian cells. The weaker risk effect of HRT than ERT may be because progesterone counteract the proliferative effect of estrogen on ovarian cells ([@B52]--[@B54]).

Between-study heterogeneity is common in meta-analysis. It is necessary to explore the potential sources of between-study heterogeneity. In this meta-analysis, a moderate between-study heterogeneity was found. However, meta-regression analysis with the covariates of study design, published year and continent revealed no source of between-study heterogeneity. After excluding two study ([@B20]) (RR \> 3.0) in the analysis of menopausal HRT and ovarian cancer, between-study heterogeneity was slightly reduced, but results did not change substantially. This indicated that the results were stable and credible.

This meta-analysis had some advantages. The first is the sufficient sample size that made the study had high statistical power to detect even small associations. Secondly, we extracted RRs reflecting the highest degree of control for potential confounders in the original studies. This will help us to get a real connection between the factors and the disease. Thirdly, sensitivity analysis showed that no individual study had excessive effects on pooled data for menopausal HRT and the risk of ovarian cancer by histologic subtypes. Fourthly, after excluding two study (RR \> 3.0) in ovarian cancer analysis, between-study heterogeneity was slightly reduced, and the results did not change substantially, suggesting that they were stable. Fifthly, in subgroup analysis stratified by the hormones types, we found both HRT and ERT could increase the risk of ovarian cancer.

However, there were still some deficiencies in this meta-analysis. First, the authors adjusted for confounders such as age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause and age at menarche etc. in original studies, but we dare not deny whether some unknown confounders might lead to exaggerating or underestimating the association. In addition, confounders adjusted for in various studies were different, which might affect the observed association. Some common biases such as selection bias, recall bias and lost to follow-up etc. in observational studies might also affect the authenticity of the results. Secondly, follow-up durations in various cohort studies differed. Some potential cases might not be observed due to limited follow-up in certain studies. Thirdly, menopausal HRT might be slightly different in each of the papers analyzed. In some papers, the HRT referred to estorgens + progestins, but in others, the HRT referred to only estorgens or estorgens + progestins. This might affect the observed association. Fourthly, the limited amount of studies assessing histologic subtypes made it difficult to confirm the relationship in terms of the kind of therapy and its association with the histological subtypes of ovarian cancer. Fifthly, although the age of subjects was over 50 years old in most included studies, a few studies covered the data from women from pre-menopausal age. This might bias the results of the meta-analysis. Sixthly, the insufficient available data prevented us from conducting a dose-response relationship to explore the association between length of HRT use and the risk of ovarian cancer.

In conclusion, this meta-analysis suggests that menopausal HRT may increase the risk of ovarian cancer, especially for serous and endometrioid tumors. This finding requires confirmation by further studies of associations of menopausal HRT with the risk of ovarian cancer in various histological subtypes.
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Forest plot of menopausal HRT and the risk of ovarian cancer in subgroup analysis stratified by geographic location. The size of a gray box is proportional to the weight assigned to the respective study, and horizontal lines represent 95% confidence intervals (CIs).
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Click here for additional data file.
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Forest plot of menopausal HRT and the risk of ovarian cancer in subgroup analysis stratified by the hormones types. The size of a gray box is proportional to the weight assigned to the respective study, and horizontal lines represent 95% confidence intervals (CIs).
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The funnel plot of menopausal HRT and the risk of ovarian cancer. Each dot represents a distinct study.
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Click here for additional data file.
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